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Abstract
Background: A new lower-cost rapid-throughput human papillomavirus (HPV) test (careHPV, Qiagen,
Gaithersburg, USA) has been shown to have high sensitivity for the detection of high grade cervical
intraepithelial neoplasia.
Methods: We assessed the outcomes and cost-effectiveness of careHPV screening in rural China, compared to
visual inspection with acetic acid, when used alone (VIA) or in combination with Lugol’s iodine (VIA/VILI). Using
data on sexual behaviour, test accuracy, diagnostic practices and costs from studies performed in rural China, we
estimated the cost-effectiveness ratio (CER) and associated lifetime outcomes for once-lifetime and twice-lifetime
screening strategies, and for routine screening at 5-yearly, 10-yearly and IARC-recommended intervals. The optimal
age range for once-lifetime screening was also assessed.
Results: For all strategies, the relative ordering of test technologies in reducing cervical cancer incidence and
mortality was VIA (least effective); VIA/VILI; careHPV@1.0 pg/ml and careHPV@0.5 pg/ml (most effective). For once-
lifetime strategies, maximum effectiveness was achieved if screening occurred between 35-50 years. Assuming a
participation rate of ~70%, once-lifetime screening at age 35 years would reduce cancer mortality by 8% (for VIA)
to 12% (for careHPV@0.5) over the long term, with a CER of US$557 (for VIA) to $959 (for careHPV@1.0) per life year
saved (LYS) compared to no intervention; referenced to a 2008 GDP per capita in Shanxi Province of $2,975.
Correspondingly, regular screening with an age-standardised participation rate of 62% (which has been shown to
be achievable in this setting) would reduce cervical cancer mortality by 19-28% (for 10-yearly screening) to 43-54%
(using IARC-recommended intervals), with corresponding CERs ranging from $665 (for 10-yearly VIA) to $2,269 (for
IARC-recommended intervals using careHPV@1.0) per LYS.
Conclusions: This modelled analysis suggests that primary careHPV screening compares favourably to visual
inspection screening methodologies in rural China, particularly if used as part of a regular screening program.
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Background
Cancer of the uterine cervix is associated with a sub-
stantial burden of disease and is a significant cause of
death amongst women in the People’s Republic of
China. The number of cases of cervical cancer in China
is estimated to have increased by 14% over the period
from 2000 to 2005 [1]. In the absence of substantial
intervention, the number of new cases is projected to
further increase over the next several decades, due to
population ageing [2]. There may be considerable het-
erogeneity in rates of cervical cancer within China, and
the evidence is consistent with a higher burden of dis-
ease in some rural areas [2].
Various approaches to screening in rural China and
other low resource settings have been considered. Given
the critical nature of the role of human papillomavirus
(HPV) infection in the causation of cervical cancer, a
potential screening strategy is to perform primary test-
ing for infection with high risk types of HPV. However,
to date, the higher cost of HPV DNA testing has pre-
cluded its use as part of large scale screening programs
in low resource settings. More recently, efforts have
been made to develop a lower cost rapid throughput
test. CareHPV is a new technology which has been
developed via a public/private partnership between Qia-
gen Inc (Gaithersburg, MD) and PATH (Seattle, WA,
USA), which has been shown to have high sensitivity for
detection of cervical intraepithelial neoplasia grade 2
and above (CIN2+) in rural China [3]. The only realistic
currently available screening alternatives to careHPV in
this setting are visual inspection techniques; cytology-
based approaches are difficult to implement due to the
need for high levels of quality assurance and ongoing
training, and HPV screening with technologies used in
developed countries, such as Hybrid Capture 2 (HC2,
Qiagen, Gaithersberg, MD), is likely to be too expensive
to implement on a large scale. HPV vaccination offers
an additional cervical cancer prevention strategy, but if
it should become available and affordable in rural China
in the near future, optimal outcomes will be achieved if
vaccination of younger cohorts is implemented in con-
junction with screening of older cohorts [4].
The objective of the current study was to perform a
comprehensive assessment of the cost-effectiveness and
impact on cancer incidence and mortality of various
screening strategies, focusing on assessing the relative
benefits of careHPV and visual inspection screening in
rural China. We utilised detailed epidemiological data
on sexual behaviour, HPV infections, test accuracy and
costs in rural Shanxi province [3,5,6] to construct a
mathematical model of HPV infection, cervical intrae-
pithelial neoplasia (CIN), and cervical screening. We
simulated screening with careHPV at 0.5 pg/ml and 1.0
pg/ml thresholds, and compared the findings to those
for screening with visual inspection using acetic acid,
when used alone (VIA) or in combination with Lugol’s
iodine (VIA/VILI). For each screening test, a number of
different strategies were considered, including once- or
twice-lifetime mobile screening strategies which would
screen women aged 35 and/or 45 years; or regular pro-
gram-based screening among women aged 30-59 years,
at 10-yearly, 5-yearly or International Agency for
Research on Cancer (IARC)-recommended intervals (for
cytology) of every 3 years in women aged 25-49 years
and every 5 years in women aged 50-64 years [7]. We
calculated the cost-effectiveness of each of these poten-
tial strategies, in order to provide data for health care
decision makers on potentially feasible screening options
using currently available technology.
Methods
Structure and parameterisation of the HPV transmission
and natural history models
We performed a dynamic simulation of HPV transmis-
sion in rural China, which was based on a reanalysis of
self-reported sexual behavioral data for a population of
662 females aged 15-59 years in Yangcheng County,
Shanxi Province; these data were originally collected via
a survey performed by IARC and the Cancer Institute
of Chinese Academy of Medical Sciences (CICAMS) [5].
The structure of the transmission model was based on
previously developed models for Finland and Australia
[8,9]. No data on male or high risk female behaviour
were available from the survey. Therefore, we assumed
that male behaviour was as reported for females, and
took a fitting approach to estimate behaviour in high
risk groups; adjusting the annual number of the part-
nerships in a small group (9%) of males and females
over 40 years of age, such that the predicted HPV pre-
valence in females corresponded to the observed age-
specific cross-sectional prevalence in the IARC survey
[5] (Table 1).
We adapted and updated a previously developed Mar-
kov model of CIN and invasive cervical cancer natural
history [10], which was informed by published data on
the probability of CIN3 progressing to invasive cervical
cancer [11]. We used a standard assumption in cervical
cancer evaluations, that CIN natural history (but not
HPV infection) is similar in different populations world-
wide. The parameters for CIN progression and regres-
sion (but not for HPV infection rates) were based on a
review of the literature [12] and were then more pre-
cisely estimated, as previously described, using data
from a well-characterised screened population (Austra-
lia) after accounting for detailed screening behaviour
and screening test accuracy [12]. For rural China, stage-
specific invasive cancer survival was based on average
survival rates from the International Federation of
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Table 1 Model parameters for screening, diagnosis, treatment and utilities; and ranges for sensitivity analysis
Parameter Baseline
value
Range for sensitivity
analysis
Screening and test characteristics
Screening participation rate for once-lifetime screening (%)† 71 40 - 100
Proportion of women never screened in lifetime in program-based screening (%)†† 15
Total participation rate over one screening round for program-based screening (age-standardised to local
population for 30-59 years) (%)†
62 35 - 100
Rate of technically inadequate tests for careHPV (%)†† 0 0 - 10
Rate of loss to follow-up after screening, diagnosis or treatment (if follow-up not performed the same day)
(%)††
10 5 - 20
Age-specific rate of unsatisfactory visual tests if performed as first visual test in management process (VIA,
VIA/VILI or colposcopy) (%)‡
20-34 years 5 0 - 5
35-39 years 6 0 - 6
40-44 years 7 0 - 7
45-49 years 16 0 - 16
50-54 years 35 0 - 35
55+ years 59 0 - 59
Conditional probability of an unsatisfactory colposcopy, given a prior unsatisfactory visual test (%)‡ 92 80 - 100
LEEP treatment success rate (%) [12] 93.6 90 - 100
Age-standardised annual progression rate from CIN3 to cancer (%) [11] 1.4 0.7 - 2.8
Proportion of CIN3 treated by hysterectomy in rural Chinese settings (%) 21.1 5 - 21.1
5-year survival by FIGO stage (%) [13]
(+/-10% of baseline values)
FIGO I 88.0 79.1 - 96.7
FIGO II 68.0 61.2 - 74.8
FIGO III 41.3 37.2 - 45.5
FIGO IV 15.5 13.9 - 17.0
Sexual behaviour parameters
Per-partnership HPV transmission probability [9] 0.6 -
Age group and sexual behaviour group mixing probability††
Same five-year age group mixing 0.7 -
Random age group mixing 0.3 -
Same sexual activity group mixing (four activity groups) 0.7 -
Random sexual activity group mixing 0.3 -
Average age-specific new annual partnerships (across sexual activity groups) in females/ males‡‡
10-14 years 0.000/ 0.000 -
15-19 years 0.097/ 0.094 -
20-24 years 0.316/ 0.263 -
25-29 years 0.029/ 0.029 -
30-34 years 0.008/ 0.008 -
35-39 years 0.045/ 0.053 -
40-44 years 0.039/ 0.047 -
45-50 years 0.075/ 0.075 -
50-54 years 0.021/ 0.021 -
55+ years 0.011/ 0.011 -
Aggregated costs (in US$)*
VIA ($) - once or twice-lifetime (mobile) screening at district hospital 3.55 2.84 - 4.26
VIA ($) - program-based screening at county hospital 4.30 3.44 - 5.16
VILI ($) - district or county hospital 0.40 0.32 - 0.48
careHPV total cost - self-sampling ($)
(including labour cost, assuming test cost = US$5)
9.20 7.20 - 14.20
careHPV total cost - provider-sampling ($)
(including labour cost, assuming test cost = US$5)
10.34 8.34 - 15.34
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Gynecology and Obstetrics (FIGO) [13]. In order to cal-
culate age-standardised cancer incidence and mortality
rates, we applied the world standard population accord-
ing to Ahmad et al [14]. Because comprehensive local
data on cervical cancer incidence and mortality were
not available, we assessed the predicted age-specific can-
cer incidence in relation to the average value for 24 less
developed countries using data from IARC’s Cancer
Incidence in Five Continents [15].
Structure and parameterisation of the screening,
diagnosis and treatment model
Shanxi province is divided into 119 counties incorporat-
ing over 1000 townships or communities, with villages
being the lowest administrative units within each com-
munity. Villages are usually equipped with a small
health clinic, whereas large hospitals are generally
located in the county-level cities. The screening and
management pathways considered in this study
included: mobile screening conducted by screening
teams travelling to villages, visiting each village on aver-
age either once or twice in the lifetime of the target
population; versus programs for repeated recall for
screening at centralised county hospitals, which would
potentially occur at 10-yearly, 5-yearly or IARC-
recommended intervals. These viable and locally accep-
table methods of screening organisation were deter-
mined in consultation with local clinicians and CICAMS
epidemiologists (Personal Communication, Professor
You-Lin Qiao). Screening participation assumptions
were informed by unpublished data from a government-
sponsored VIA/VILI screening demonstration project in
3,492 women aged 30-59 years who were screened using
VIA/VILI in Xiangyuan, Shanxi Province in 2006 (Perso-
nal Communication, Professor You-Lin Qiao). Based on
these data, we assumed an overall participation rate of
71% for one screening round implemented by a mobile
service. To take into account the reduced screening cov-
erage reported at older ages in the demonstration pro-
ject, for regular program-based screening conducted at
county hospitals we assumed age-specific participation
patterns, with an overall age-standardised participation
rate of 62% in screened age groups (Table 1).
Figure 1 depicts the structure of the screening, diag-
nosis and treatment pathways used for each of the test
modalities; model parameters for screening and diagno-
sis are summarised in Tables 1 and 2. For VIA, test
positives were assumed to have immediate colposcopy,
and therefore no women were lost to diagnostic follow-
up; for combined VIA/VILI strategies, VIA positives had
Table 1 Model parameters for screening, diagnosis, treatment and utilities; and ranges for sensitivity analysis
(Continued)
LEEP ($) 55.95 44.76 - 67.13
Cancer treatment cost ($):
FIGO I 627.64 502.11 - 753.16
FIGO II 1953.20 1562.56 - 2343.83
FIGO III 1810.17 1448.13 - 2172.20
FIGO IV 662.61 530.09 - 795.1
Discount rate (%) [24] 3.6 0 - 5
Secondary analysis of utilities (reference = 1.0 for perfect health) [19-21]
Having a screening test 0.999945 0.999616 - 0.999956
Screening test positive with no treatment on the same day 0.999918 0.998849 - 0.999934
Colposcopy negative 0.999877 0.998274 - 0.999901
Colposcopy positive and biopsy negative 0.9965 0.992603 - 0.997238
Colposcopy positive then biopsy confirmed CIN1 with no treatment 0.9965 0.992603 - 0.997238
Colposcopy positive then biopsy confirmed CIN1 with LEEP treatment 0.984 0.935178 - 0.987178
Colposcopy positive then biopsy confirmed CIN2-3 with LEEP treatment 0.984 0.935178 - 0.987178
Colposcopy positive then biopsy confirmed CIN3 with hysterectomy treatment 0.85 0.82 - 0.88
Cancer - FIGO I 0.76 0.65 - 0.76
Cancer - FIGO II 0.67 0.56 - 0.67
Cancer - FIGO III 0.67 0.56 - 0.67
Cancer - FIGO IV 0.67 0.48 - 0.67
†
Data source: Professor You-Lin Qiao, personal communication (based on a demonstration screening project in Xiangyuan County, Shanxi Province 2006);
†† Assumption (no data available);
‡ Re-analysis of data on colposcopy unsatisfactory rates from Dai et al [5];
‡‡ Female data were based on re-analysis of the IARC/CICAMS study [5], and male sexual contact data were assumed based on female data;
* Micro-costing study results as described in text. Range for sensitivity analysis +/-20% of baseline values.
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immediate colposcopy whereas VIA negatives under-
went VILI testing. However, VILI-positive women could
not have immediate colposcopy since the use of Lugol’s
iodine precludes full colposcopic examination with
acetic acid; in this case colposcopy after positive VILI
was assumed to be performed on the next day with
some women (10%) lost to follow-up. An age-specific
probability of having unsatisfactory visual inspection
results (in which the original squamocolumnar junction
was not fully visible) was incorporated using data from a
previous study [5]. A proportion (10%) of women with
unsatisfactory but negative VIA or VILI test results were
B. VIA/VILI strategies
VIA test
Colposcopy
VILI test
pos
neg
sat
unsat
pos
Loss to F/U
End this
screening round
neg
Loss to F/U
pos
neg
Colposcopy
on next visit
Colposcopy 
on next visit
sat
unsat
End this
screening round
Biopsy
ECC + Biopsy
ECCECC†
pos
neg
pos
neg
sat
unsat
End this
screening round
Biopsy
ECC + Biopsy
ECC
pos
neg
pos
neg
End this
screening round
D. ECC/biopsy and treatment procedures
Cancer 
treatment‡
Recall for
treatment
Lost to F/U
Histologic
invasive 
cancer
Histologic
CIN2/3
Attend for
treatment
Hysterectomy‡‡
LEEP
End this
screening round
Histologic
CIN1
End this
screening round
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End this 
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If treated*
If not treated
LEEP
Lost to F/U
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VIA test
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neg
sat
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End this
screening round
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unsat
End this
screening round
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ECC + Biopsy
ECC
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neg
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End this
screening round
ECC†
Colposcopy
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clinician-sampling)
C. careHPV strategies
sat
unsat
End this
screening round
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neg
Loss to F/U
Re-sample 
/ re-test
neg
Loss to F/U††
End this
screening round
Colposcopy
pos
technically
inadequate
technically
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Figure 1 Screening and management pathways. pos = positive result; neg = negative result; sat = original cervical squamocolumnar junction
fully visible. † A proportion (10%) of women with unsatisfactory and negative VIA or VILI test results were assumed to undergo endocervical
curettage (ECC) on the same day. †† If colposcopy performed on the same day as HPV sampling and laboratory testing, assumed no loss to
follow-up. ‡ Model assumes stage-specific cancer survival as described in text. ‡‡ A proportion (21%) of women with CIN3 were assumed to
receive hysterectomy treatment, based on data from the micro-costing study.* CIN1 is assumed to be treated in once or twice-lifetime strategies
only. ** Go to a sub-model of post-treatment natural history and recurrence [12].
Table 2 Summary of test characteristics for detection of CIN2+†
VIA only VIA/VILI careHPV@ 1.0 pg/ml careHPV@ 0.5 pg/ml Colposcopy
Sensitivity 41% 58% 84% (provider)
73% (self)
90% (provider)
81% (self)
81%
Specificity 95% 82% 88% (provider)
88% (self)
84% (provider)
82% (self)
77%
† Note that this table summarises the finding for sensitivity and specificity in the original study populations, taking into account the relative proportions of CIN1,
2 and 3 in the population. However, the model implementation used these data to derive a test probability matrix separately describing the relationship
between each health state (Normal; PCR HPV positive; CIN1, CIN2, CIN3+, etc.) and each test, rather than utilising the study sensitivity and specificity estimates
directly, as described in the text [3,5,6].
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assumed to undergo endocervical curettage (ECC) on
the same day (Figure 1). We also incorporated an age-
specific unsatisfactory rate for colposcopy, which was
based on local data [5,16].
For careHPV strategies, alternative sampling methods
and different thresholds for test positivity were consid-
ered. In mobile screening strategies involving one or
twice lifetime screening, it was assumed that women
would perform self-sampling, and that specimen ana-
lyses would occur in a community or village clinic. For
regular screening strategies where women attend the
county hospital for screening, cervical samples were
assumed to be taken by a health care provider. In both
cases it was assumed that samples were processed on
the same day, with HPV-positive women receiving
immediate colposcopy and directed biopsy (as required).
For all strategies, we assumed diagnostic confirmation
of the screening results would occur prior to any treat-
ment, because after extensive consultation with local
decision-makers it was determined that in this setting
“see-and-treat” procedures would not currently be clini-
cally acceptable. The diagnostic process involved colpo-
scopy, directed biopsy, and ECC for a proportion of
women with unsatisfactory colposcopy (Figure 1). The
majority of women with a histologically-confirmed
CIN2/3 were assumed to be treated with the loop elec-
trosurgical excision procedure (LEEP). For once or twice
lifetime screening strategies, we also assumed that all
histologically-confirmed CIN1 were treated by LEEP.
We applied a baseline estimate of a 94% success rate for
LEEP based on a previous review [12] (evaluating the
range 90%-100% in sensitivity analysis).
For each screening test, we characterised the probabil-
ity of a positive test result given a satisfactory test and
given the underlying health states in the natural history
model, which included normal, HPV infected (approxi-
mated as PCR-HPV positive), CIN1, CIN2, CIN3 and
stage-specific undiagnosed and diagnosed cancer states.
In order to characterise the accuracy of careHPV test-
ing, we used the findings of a cross-sectional study con-
ducted in 2,388 women in rural Shanxi Province [3]. In
this study, careHPV testing from cervical samples taken
by a health provider was found to have sensitivities for
CIN2+ of 90% and 84% at cut-off thresholds of 0.5 pg/
ml and 1.0 pg/ml, respectively; with corresponding test
specificities of 84% and 88%. The study also found that
the sensitivity of careHPV testing for CIN2+ when
women provided self-sampled vaginal specimens was
comparable but slightly lower than that of cervical spe-
cimens (Table 2). Two studies conducted in Shanxi Pro-
vince have examined the accuracy of VIA screening
compared to a “gold standard” diagnosis based upon 4-
quadrant biopsy; and both found that in this setting the
sensitivity of VIA testing was low at 41-46%, but with a
corresponding high specificity of 92-95% [3,17] and we
used these data in the model (Table 2). To characterise
VILI accuracy after negative VIA, we reanalysed data
from a Yangcheng County study [5,16] and adjusted the
sensitivity of VILI testing downwards to account for a
potential inflation of up to 20 percentage points in sen-
sitivity in studies of visual inspection which use colpo-
scopic-directed biopsy as the gold standard [17]. For
colposcopy performance, we used data from a study
which assessed colposcopic accuracy against 4-quadrant
biopsy, which found that colposcopy had an 81% sensi-
tivity for CIN2+ [6]. The assumed test characteristics
are summarised in Table 2.
Costs
We performed a micro-costing study for costs asso-
ciated with the delivery of screening and diagnostic tests
and LEEP at the Women and Children’s Hospital in
Xiangyuan County, Shanxi Province in April 2008. This
hospital has been the focus of previous population-
based cervical screening studies and demonstration pro-
jects [18]. The costing study was conducted as one com-
ponent of a larger government-sponsored cervical
screening demonstration project, which was approved
by the Institutional Review Board of the Cancer Founda-
tion of China. The costing was undertaken from a socie-
tal perspective and included both direct medical costs
and direct nonmedical costs. The resources (consum-
ables, equipment and staff time) associated with clinic
visits and laboratory testing were identified using obser-
vational field work and extensive consultation with local
medical staff. Each item was costed at 2008 prices from
financial records at the hospital. Transportation costs
were estimated based on a prior demonstration project
in Shanxi Province [18], in which the women were
transferred between their home villages and the county
hospital for screening (personal communication, Prof.
You-Lin Qiao). We also conducted a detailed assessment
of the overhead costs associated with delivering the
screening program, including infrastructure, recruit-
ment, data administration, training, quality control and
staff transportation costs. For attribution of these over-
head costs we estimated that on average 60 women
would be screened each day after full implementation of
the screening initiative. The test cost for careHPV in the
base case was assumed to be US$5, not including labour
and overhead costs.
Invasive cancer treatment costs by the FIGO stage
were also obtained from the government-sponsored
demonstration project in Shanxi Province. These direct
medical costs were obtained from an audit of hospital
charges in three hospitals: the Cancer Hospital of Shanxi
Province (a provincial-level referral centre), the affiliated
hospitals of Changzhi Medical College, Changzhi City
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(city level) and the Women and Children’s Hospital of
Xiangyuan County (county level). To identify the direct
nonmedical costs associated with invasive cancer treat-
ment, 192 patients with invasive cervical cancer were
interviewed at the three hospitals. For the current analy-
sis we assumed a charge/cost ratio of 1.25, and we also
assumed that all FIGO I and FIGO IV patients are trea-
ted at county hospitals and that FIGO II/III patients are
treated at city hospitals (50%) and provincial hospitals
(50%). The final aggregated costs for screening, diagno-
sis and treatment procedures are presented in Table 1.
Utilities
The primary results of the current analysis were based
on estimates of life-years saved (LYS). However, as a
secondary analysis, we also performed an indicative eva-
luation of the impact on quality-adjusted life years saved
(QALYs) for various screening strategies. In order to
estimate QALYs, some health states in the model were
assigned a disutility value. These included utilities which
reflected the experience of being screened; having a
positive screening test; having a confirmed precancerous
lesion with treatment; and having invasive cervical can-
cer (according to stage). The weightings were informed
by an international literature review, because compre-
hensive information on utilities are not available for
rural China (Table 1) [19-21].
Effectiveness and resource utilisation outcomes
For each strategy we estimated the age-standardised
incidence and mortality of invasive cervical cancer
(across all ages) and the cumulative lifetime risk of
developing invasive cancer to age 65 years. For once-
lifetime screening strategies we also calculated the num-
ber of colposcopies, biopsies and treatments associated
with the use of each screening test, and the ratio of the
number of colposcopies to the number of treatments
performed. Furthermore, for once-lifetime screening, we
performed an analysis of the optimal age of screening by
calculating the life years saved for a range of screening
ages. Because this analysis was designed to assess the
optimal age range for a single round of screening in a
population, we did not discount the life years saved for
the calculation.
Cost-effectiveness analysis
We took a societal perspective for the cost-effectiveness
analysis, in accordance with World Health Organization
(WHO) recommendations for health economic assess-
ments [22]. All costs and cost-effectiveness ratios were
originally calculated in Chinese Yuan (CNY) and then
converted to 2009 US dollars (exchange rate: 1 USD =
6.8304 CNY; 19 May 2009). All costs and effects were
discounted (according to standard methods [23]) at 3.6%
(the interest rate used by the Bank of China in 2008)
[24]. The 3% discount rate recommended by WHO for
cost-effectiveness assessments in developing countries
[22] was included in the range assessed in sensitivity
analysis. Cost-effectiveness ratios (CERs) were compared
to an indicative threshold value of the estimated gross
domestic product (GDP) per capita in Shanxi Province
in 2008 [25], which was equivalent to US$2,975. Strate-
gies less than this value are considered “very cost-effec-
tive"; and all strategies less than three times this value
are considered “cost-effective” [26].
We calculated the cost-effectiveness of the different
screening strategies in two different ways. Firstly, we cal-
culated the CER for each strategy as cost per life year
saved in relation to no intervention. This measure of
cost-effectiveness does not assume that all test technolo-
gies are equally standardisable, reliable over the long
term, or acceptable. Secondly, we assessed cost-effective-
ness if all strategies are considered equally feasible, and
in this case calculated the Incremental CER (ICER) in
relation to the next most cost-effective strategy. The
first methodology reflects the policy-maker decision fra-
mework in the current setting, which currently has no
widespread organised screening initiatives. Furthermore,
it allows the analysis to independently consider the cost-
effectiveness of each technology, which is potentially
more appropriate in the current evaluation, since the
standard cost-effectiveness analysis methodology can not
take into account issues of stakeholder acceptability, test
reliability or potential change or degradation in test per-
formance over time for all the test methodologies
included in the incremental cost-effectiveness analysis.
Sensitivity analysis and supplementary calculations
Univariate sensitivity analysis was performed to assess
the effect of model assumptions on the study findings,
with the range of values used for sensitivity analysis
given in Table 1. The range was chosen to reflect clini-
cally feasible ranges and/or to encompass a wide range
of possibilities. The primary analysis for the current
study adopted a population perspective which takes
achievable levels of screening participation into account.
For comparison of the findings with a prior cost-effec-
tiveness study on screening in other lower resource set-
tings [27], we also calculated the reduction in lifetime
risk of cancer in screened women only. We also assessed
the impact of assuming perfect colposcopic accuracy for
all health states, perfect sensitivity of the screening and
diagnostic processes for detection of invasive cancer, no
loss to follow-up in the diagnostic process, and no unsa-
tisfactory test results. For the secondary analysis of cost-
effectiveness using QALYs, we tested the effect of vary-
ing utilities within the range reported in the interna-
tional literature.
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We also performed a supplementary analysis to test
the effect of assumptions about the natural history of
HPV infection in women over 35 years of age on the
calculated efficacy of once-lifetime careHPV screening.
In the baseline model, prevalent infections observed in
older women were assumed to be a mix of new infec-
tions and persisting infections; with the relative propor-
tion of these at particular ages determined by the
predictions of the dynamic transmission model (which
was informed by reported female sexual behaviour in
this population, as previously described). In this model
implementation, it was assumed that all infections in
older women had an equal probability of progression to
CIN 3 and thus to invasive cancer. However, it is not
known to what degree the HPV infections observed in
women over 35 years in this population represent new
infections acquired via new female or male partner con-
tacts, or whether some (or most) of the prevalent infec-
tions represent persisting or previously latent but re-
emerging infections, or to what degree cohort effects are
evident in the relatively high rates of infection observed
in the cross-sectional data for older women. Because of
these uncertainties, the significance and potential for
progression of a prevalent HPV infection in older
women in this population is not well understood. There-
fore, in a supplementary analysis we calculated the aver-
age reduction in cervical cancer lifetime incidence and
mortality under the extreme assumption that all infec-
tions observed in women aged 35 years or older were
persistent and had been originally acquired at younger
ages, and were thus potentially detectable at a screening
event at age 35 (this assumption would imply the high-
est possible efficacy for once-lifetime primary HPV
screening at this age).
Results
HPV prevalence and cancer incidence and mortality, in
the absence of intervention
Figure 2A shows the measured and modelled age-specific
oncogenic HPV prevalence in Shanxi Province (the HPV
types implicated in cancer have been defined as oncogenic
or “high risk” by the IARC [28]). The measured prevalence
(using the HC2 test, which detects 13 HPV types, includ-
ing HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58,
-59, and -68) shows a “flat” or potentially “double-peaked”
pattern, with relatively low levels of oncogenic HPV infec-
tion compared to developed countries but with relatively
high rates in women over 40 years of age compared to
younger women [5]. The measured age-standardised rate
of infection for cytologically normal women aged 15-59
years was 8.1% (95%CI: 2.1% - 13.6%), and the model-
fitted age-standardised prevalence was 8.2%.
We used a dynamic model of sexual behaviour and
HPV transmission to estimate HPV incidence by single
year of age, taking into account previously reported
assumptions about the duration of infection and of
naturally-acquired immunity [8,9]. The incorporation of
the HPV incidence into the model of CIN natural his-
tory resulted in a predicted age-standardised incidence
of invasive cervical cancer of 19.0 per 100,000 women,
and a cumulative lifetime risk of cervical cancer of 2.9%
(to age 85 years). These predictions are similar to the
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average age-standardised incidence of 22 per 100,000
(using the Segi world standard population), and the
average cumulative lifetime incidence of 2.7%, observed
in developing countries without substantial levels of
screening calculated using data from IARC’s Cancer
Incidence in Five Continents Vol. VIII [14,15]) (Figure
2B). However, the age-specific patterns of invasive can-
cer in this population are predicted to differ somewhat
from that in other populations, with the lower HPV
infection rates in younger women resulting in lower
rates of invasive cancer in women under 60 years of age
(Figure 2B). The model also predicts an age-standar-
dised cervical cancer mortality rate of 9.9 per 100,000 in
the absence of any intervention; and a mortality to inci-
dence ratio of 0.52 in this rural population, which is
similar but slightly higher than the estimated overall
ratio for China of 0.44 [29].
Cancer incidence and mortality outcomes after screening
interventions
Table 3 shows the predicted reductions in cervical can-
cer incidence and mortality and the cumulative lifetime
risk of developing invasive cervical cancer to age 65
years. For all screening strategies assessed, the relative
ordering of test technologies in terms of reduction in
cervical cancer incidence and mortality was VIA-only
(least effective); VIA/VILI; careHPV@1.0 pg/ml thresh-
old; and careHPV@0.5 pg/ml (most effective). Once-life-
time screening strategies are predicted to reduce cancer
incidence and mortality in the overall population by
between 7-12% (depending on the test technology), with
this reduction increasing to 13-24% for twice-lifetime
screening strategies or to 17-54% for regular screening
strategies. The reductions in mortality are predicted to
be slightly higher than those for incidence, due to the
effect of screening on detection of asymptomatic inva-
sive cancer and some consequent downstaging. Compar-
able reductions are predicted in the cumulative lifetime
incidence to age 65 years (Table 3).
Resource utilisation and optimal age range for once-
lifetime screening
In order to assess differences in colposcopy referral and
treatments performed for each of the screening tests, we
calculated the predicted number of colposcopies, biop-
sies and treatments for once-lifetime screening. Table 4
details the numbers of each procedure performed after
screening 100,000 women with each screening test at
age 35 years. The number of colposcopies performed is
related to the specificity of the screening test, and in
this setting we found that approximately 6% of screened
women would be referred to colposcopy after VIA
screening, compared to approximately 8% of women
after self-sampling with careHPV testing (Table 4). The
predicted number of biopsies and treatments takes into
account the mix of underlying natural histories referred
to colposcopy by the screening test, the accuracy of col-
poscopy for each natural history state, and compliance
with follow-up for additional visits. The colposcopy/
treatment ratio, when considered in conjunction with
the lifetime effects on cancer incidence and mortality,
provides a measure of the efficiency of the screening
and diagnostic process. CareHPV testing results in a
colposcopy/treatment ratio of approximately 5 for either
test threshold, whereas this is increased by 50% for VIA
only (7.7) and over 300% for VIA/VILI testing (17.3),
showing that fewer women are receiving unnecessary
colposcopy in the case of careHPV. For once-lifetime
screening strategies, maximum effectiveness in terms of
life years saved for all screening tests was achieved if
screening was performed between 35-50 years, with atte-
nuated benefits in screening at ages over about 50-55
years (Figure 3).
Cost-effectiveness outcomes
When compared to no intervention, all strategies would
be considered cost-effective, because the cost per life year
saved (CER) in relation to no intervention is in all cases
considerably lower than the GDP per capita for Shanxi
Province in 2008 (Table 3). Figure 4A provides a repre-
sentation of the incremental cost-effectiveness of the
strategies, showing the cost-effectiveness plane for costs
versus life years and the relationship between screening
technology, screening frequency and the relative
increases in costs and effects. Using this method for
assessing cost-effectiveness, strategies on the frontier
(bottom right) of the cost-effectiveness plane are consid-
ered to be cost-effective. In this evaluation the visual
inspection strategies that we assessed were generally
found to be cost-effective (assuming consistent test per-
formance over time), with VIA strategies at higher
screening frequencies tending to dominate careHPV stra-
tegies at lower frequencies; this was driven by the low
cost of visual inspection testing. As a further supplemen-
tary outcome we also calculated the ICER relative to the
next most effective strategy using cost per QALYs (Figure
4B). The relative ordering of the strategies was generally
unchanged when QALYs were considered; again, the
visual inspection strategies at higher frequencies tended
to dominate the careHPV strategies, assuming consistent
test performance over time. We also assessed the propor-
tional breakdown of costs as a percentage of the total life-
time cost of screening and treatment for various
screening strategies, and these are presented in Figure 5.
Sensitivity analysis and supplementary calculations
For all screening strategies, the cost-effectiveness find-
ings were most sensitive to assumptions about the
Shi et al. BMC Cancer 2011, 11:239
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Table 3 Predicted effect of screening strategies on cancer rates and cost-effectiveness
Screening
strategy and
test
Average lifetime
reduction cancer
incidence
Average lifetime
reduction cancer
mortality
Average reduction
cumulative incidence 0-64
years
Cost-effectiveness ratio compared to
no intervention (US$ / LYS) †
Once-lifetime (35
years)
VIA only 7% 8% 8% 557
VIA/VILI 8% 10% 10% 629
careHPV@1.0 pg/
ml
10% 12% 12% 959
careHPV@0.5 pg/
ml
10% 12% 13% 909
Twice-lifetime
(35+45 years)
VIA only 13% 16% 17% 611
VIA/VILI 16% 18% 20% 689
careHPV@1.0 pg/
ml
19% 22% 24% 1,032
careHPV@0.5 pg/
ml
21% 24% 25% 985
10 yearly (30-59
years)
VIA only 17% 19% 20% 665
VIA/VILI 19% 22% 23% 744
careHPV@1.0 pg/
ml
24% 28% 29% 1,074
careHPV@0.5 pg/
ml
24% 28% 29% 1,071
5 yearly (30-59
years)
VIA only 27% 32% 33% 796
VIA/VILI 31% 36% 37% 916
careHPV@1.0 pg/
ml
37% 43% 44% 1,395
careHPV@0.5 pg/
ml
37% 43% 44% 1,391
IARC
recommended
VIA only 37% 43% 41% 1,213
VIA/VILI 41% 47% 45% 1,427
careHPV@1.0 pg/
ml
47% 54% 52% 2,269
careHPV@0.5 pg/
ml
48% 54% 52% 2,263
† Comparison GDP per capita Shanxi Province 2008: US$ 2,975 [25].
Table 4 Predicted number of procedures per 100,000 women screened at age 35 years
Screening test Colposcopy Biopsy† Treatment for precancerous lesions Colposcopy/ treatment ratio
VIA only 6,068 1,920 791 7.7
VIA/VILI 17,881 4,640 1,036 17.3
careHPV@1.0 pg/ml 8,124 3,010 1,493 5.4
careHPV@0.5 pg/ml 8,478 3,164 1,587 5.3
† Biopsy does not include diagnoses from ECC.
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progression rate from CIN3 to invasive cervical cancer,
the discount rate, cancer survival assumptions (which
affect the predicted mortality to incidence ratio), the
cost of careHPV testing and VIA, test accuracy, and
cancer treatment costs. The results of the sensitivity
analyses are detailed in Figure 6 (for LYS outcomes) and
Figure 7 (for QALY outcomes). The sensitivity analysis
included consideration of a wide range of test character-
istics for careHPV testing, in order to assess the impact
of uncertainty about the accuracy of the test when
translated to large-scale field implementation. If the sen-
sitivity of careHPV testing for detection of CIN2+ were
reduced to 60%, the estimated reduction in cancer inci-
dence and mortality would decrease to between 8-45%
(depending on the screening frequency).
In order to compare our findings for once-lifetime
screening with those of a previous analysis in five
developing countries (not including China) [27], we cal-
culated the reduction in lifetime risk of invasive cervical
cancer (to age 65 years) under two additional sets of
assumptions. Firstly, we assumed lifetime risk was calcu-
lated in screened women only rather than taking a
population perspective as for the current analysis. This
increased the relative reduction in lifetime risk of inva-
sive cervical cancer to between 8-13% (depending on
the test technology in screened women). Secondly, we
adopted other key assumptions of the prior analysis,
including see-and-treat procedures for visual inspection
and HPV screening strategies, an assumed sensitivity for
CIN2+ for colposcopy, VIA and HPV testing of 100%,
76% and 88%, respectively; and no unsatisfactory visual
tests. Under these assumptions the predicted reduction
in lifetime incidence after a single screening test at age
35 years in screened women was between 21% (for VIA)
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Figure 5 The proportional breakdown of costs of screening and treatment for selected strategies. A. Once-lifetime screening with VIA/
VILI at age 35 years; B. Once-lifetime screening with careHPV@0.5 pg/ml at age 35 years; C. Routine screening with VIA/VILI at IARC-
recommended intervals; D. Routine screening with careHPV@0.5 pg/ml at IARC-recommended intervals. The greatest component of the total
lifetime cost is the cancer treatment cost for once-lifetime screening strategies. In contrast, for screening according to the IARC-recommended
intervals (the most intensive regular screening strategy examined) the screening test costs dominate.
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Figure 6 Sensitivity analysis for cost per life year saved (LYS). Sensitivity analysis findings are shown for cost-effectiveness ratios relative to
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and 24% (for careHPV testing). This is broadly consis-
tent with the result of the prior analysis which found
that once-lifetime testing at age 35 years would be asso-
ciated with a reduction of between 25-36% in lifetime
risk to age 65 years in screened women [27]. The differ-
ences in the assumed sensitivity of the screening tests,
the perspective taken (screened individual vs population
perspective) and to some extent the requirement for col-
poscopic confirmation in the current context explained
most of the differences between our study findings and
that of the prior analysis.
Under the extreme assumption that all infections
observed in this population at age 35 years or older
were persisting and were originally acquired at a
younger age (the assumption most favourable to once-
lifetime careHPV screening at age 35 years), the average
lifetime reductions in cancer incidence and mortality
after once-lifetime careHPV screening at 0.5 pg/ml are
predicted to increase to 26% and 27%, respectively.
Therefore, under these differing assumptions about the
natural history of HPV in older women, the predicted
lifetime reductions in cancer rates associated with once-
lifetime screening with careHPV are predicted to
increase by more than a factor of two.
Discussion
To our knowledge, this is the most detailed modelled
evaluation of cervical cancer screening to be conducted
in China. The analysis incorporated setting-specific
information on the risks of HPV infection, screening
and management procedures and the costs associated
with screening, diagnosis and treatment. The screening
alternatives considered were based on extensive consul-
tation with local key opinion leaders about the practical
options for organising screening in rural China. We
evaluated the predicted outcomes resulting from various
screening alternatives, including once or twice-lifetime
screening at ages 35 and/or 45 years by mobile screen-
ing units; and routine screening at 5-yearly, 10-yearly
and IARC-recommended intervals within a program of
regular screening. Depending on the test technology
used, and assuming a participation rate of ~70%, we
found that once-lifetime screening at age 35 years
would reduce age-standardised cervical cancer mortality
in the population by 8-12% over the long term, with a
CER of $557-959 per LYS. Regular screening at a feasi-
ble age-standardised participation rate of 62% in women
aged 30-59 years would reduce cervical cancer mortality
by 19-54%, with a CER of $665-2,269 per LYS.
Although these findings imply that all strategies would
be considered cost-effective in relation to no interven-
tion, testing with careHPV is predicted to lead to
greater absolute benefits when compared to visual
inspection tests.
The screening participation rate used in the evaluation
was informed by a government-sponsored VIA/VILI
screening demonstration project. Although the assumed
participation rate may seem relatively high in context of
developed country programs, it has been demonstrated
to be achievable locally, in the context of a high level of
population enumeration and high compliance with gov-
ernment initiatives. We found that in this population in
rural China a single round of screening can potentially
be extended from 35 year old women to women aged
up to 50 years without loss of effectiveness. This finding
is important for the practical realisation of single round
screening strategies as it implies that a reasonably wide
age range of women can be included whilst still maxi-
mising long term benefits. However, we found that the
lifetime benefits of once-off screening may be lower
than previously estimated for other populations [27]. A
previous study of the cost-effectiveness of cervical
screening in five developing countries (not including
China) concluded that once-lifetime screening at age 35
years could reduce the cumulative lifetime risk of inva-
sive cervical cancer in screened women by between 25-
36%, depending on the screening strategy and technol-
ogy used [27]. After taking into account a population
rather than an individual perspective, local information
on the sensitivity of screening tests, the local require-
ment for colposcopic confirmation of all screening test
results with consequent diagnostic accuracy loss, and
other factors, our analysis for rural China identified
more attenuated benefits. Our findings are complemen-
tary to that of a recent randomised trial in rural India
which found that a single round of HPV screening was
associated with a reduction by approximately 50% in the
hazard ratio for the development of advanced cervical
cancer and cervical cancer death over the following
eight years [30]. Over a lifetime, the relative protective
effect of a single HPV test in screened versus
unscreened women is expected to be reduced as some
new HPV infections and new cancer cases accrue in
both groups over time. Our study supplements the trial
findings by providing a measure of the benefits of a sin-
gle round of screening but considered from the stand-
point of long term (lifetime) follow-up.
Our finding that careHPV screening can be cost-effec-
tive in rural China is consistent with that of a prior ana-
lysis by Levin et al [31]. However, we focused on the
differential outcomes and cost-effectiveness associated
with visual inspection methods and careHPV testing,
considering the differential effects associated with vary-
ing the HPV test threshold or adjusting the visual meth-
odology to include Lugol’s iodine. In contrast, prior
work considered careHPV testing in relation to HC2
testing and cervical cytology, which may not be readily
practicable alternatives in this setting. Therefore, the
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current paper extends the findings of the related pre-
vious work [27,31] in two important ways - it provides
more detail for this particular setting, and it compares
the performance of careHPV screening to the other cur-
rently viable test alternatives in this setting.
Visual inspection methods have been proposed as low
cost screening solutions in less developed countries
[7,30,32]. However, problems with accuracy and test
standardisation may have hindered the widespread
adoption of visual testing modalities, and a round of
VIA screening was not associated with any significant
reduction in the risk of advanced cancer or death over
eight years of follow-up in a recent large scale trial in
India [30]. It has been suggested that in some diagnostic
accuracy studies of visual inspection methods the sensi-
tivity of the test may have been overestimated by up to
20 absolute percentage points due to verification bias
when colposcopically-directed biopsy is used as the gold
standard [17]. In order to increase the sensitivity of
visual testing, the addition of VILI has been proposed as
a secondary test for VIA-negative women [7]. The VIA/
VILI combined procedure may moderately increase the
sensitivity of visual inspection modalities [32] and has
been shown to be logistically feasible within a govern-
ment-sponsored large-scale demonstration project at 42
sites across China, which was rolled out from 2006 [18].
However, limited data are available on the accuracy of
VIA/VILI as a combined procedure. Based on re-analy-
sis of follow-up data from a previous study [5,16], we
assumed that in this setting the addition of VILI would
increase sensitivity but would decrease the overall speci-
ficity of visual inspection testing, which may not uni-
formly be the case [32]. Therefore, more data on the
accuracy of combined VIA/VILI testing is required, and
our results for this combined test modality should be
considered provisional.
This analysis has several limitations. Firstly, the model
which was used is based upon CIN natural history states
rather than states that directly reflect type-specific HPV
infection persistence and progression. It should be
noted that there are considerable uncertainties about
the natural history of HPV (and thus modelled analysis
of primary HPV testing) in populations such as the one
we studied in rural China, in which the rates of infec-
tions at older ages are comparable or higher to those at
younger ages. The relative proportion of new versus re-
emerging latent or persisting HPV infections in women
over 35 years of age in this population is not known.
Furthermore, the progressive potential of new infections
in older women in this population is difficult to charac-
terise. We did not have direct information on male sex-
ual behaviour and thus could not estimate the total rate
of new exposures in older women; therefore we took a
fitting approach to modelling the observed pattern of
female HPV infection by incorporating survey data on
female behaviour and estimating male behaviour pat-
terns. In general terms, if infections in women aged 35
years or older have a low potential to progress to CIN3
(and then to invasive cancer), then the efficacy of once-
lifetime HPV screening at age 35 would be higher. In
our baseline analysis we assumed that some new infec-
tions would progress to CIN3 after a once-lifetime
screening event. However, under the extreme assump-
tion that all HPV infections occurring in older women
that have the potential to progress to CIN 3 are poten-
tially detectable (and treatable) at the time of the
screening event, the average reduction in cumulative
lifetime incidence and mortality associated with once-
lifetime HPV screening would increase. This implies
that from the perspective of the cost-effectiveness of
once-lifetime primary HPV screening, our evaluation
has taken a conservative approach.
Another limitation of the study is that we could not
account for variation in screening and diagnostic test
performance over time, due to drift in clinical or labora-
tory practice (although we did include consideration of
the need for quality control procedures in the costs
associated with the screening strategies). Because of this
limitation, we presented our main cost-effectiveness
findings for each technology as a cost-effectiveness ratio
compared to no intervention, since the relative test per-
formance of visual inspection and HPV testing meth-
odologies may vary over time in this setting in as-yet-
unpredictable ways. Another limitation of the study is
that we did not have extensive local data on health state
preferences (utilities) or data from comparable popula-
tions to use in the calculation of QALYs, and therefore,
the primary findings of the current analysis were based
on the estimation of life years saved for the various
screening strategies.
We have extensively reviewed the available local cervi-
cal cancer incidence and mortality data. Shanxi Province
has been thought to be a “high risk” area for cervical
cancer; but in practice the evidence for this appears to
depend heavily on the findings of the earliest cancer
mortality surveys conducted in China in the 1970s
which found that rates were up to 83 per 100,000
women (according to the Segi World Standard Popula-
tion [2,33]; no information on the population according
to Ahmad et al can be calculated because age-specific
data are not available [14]). Two subsequent mortality
surveys were performed in China [2,34,35] - the most
recent in 2000-2005 included data from Xiangyuan
county in Shanxi Province, finding a much lower mor-
tality rate of 6.8 per 100,000 women [2,35] (according to
the Chinese standard population of 1982; again, age-spe-
cific data are not available to calculate rates according to
the Ahmad et al standard population). Furthermore,
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perceptions of the region as “high risk” appear inconsis-
tent with the relatively low rates of HPV infection
observed in females overall (Figure 2A in our paper).
There are no IARC-certified cancer registries in the
region and so no up-to-date accurate registry informa-
tion is available. In the absence of such information we
have taken a conservative approach to the current eva-
luation, and assumed the lifetime risk of cancer and the
average incidence rate are equivalent to the average rate
of developing countries. It should be noted that this
incidence rate is still much higher than the rate reported
for China overall according to the most recent data
from IARC’s Cancer Incidence in Five Continents [36],
which is less than 4 per 100,000 women and substan-
tially less than many developed countries. If in fact can-
cer rates are higher than we assumed in this setting, this
would have the effect of increasing the estimated cost-
effectiveness of all screening strategies, but would be
unlikely to change the relative costs and benefits of the
various strategies, compared to no intervention.
Our objective in this study was to provide policy
makers in China with the best available evidence on the
relative benefits and costs of different screening strate-
gies. Modelling is a commonly used approach, and here
we have employed the techniques of modelling to inte-
grate local evidence with international data. Modelling is
an important complement to randomised clinical trials,
but one of the advantages of modelling studies is that
they can predict lifetime epidemiologic outcome and
cost-effectiveness results. Additionally, a much greater
range of potential strategies can be evaluated via mod-
elled approaches. A total of 20 screening strategies were
evaluated in our study, but such a large number of stra-
tegies are unlikely to be practical in a large-scale screen-
ing trial. Although randomised controlled trials are
ultimately the “gold standard”, in practice these are
highly unlikely to be performed in every setting into
which cervical cancer prevention initiatives are intro-
duced. In the absence of such locally conducted trials,
modelling studies provide local policy makers with the
best available information with which to inform further
decision making.
Our experience in working with local key opinion lea-
ders and policy makers in China emphasises the impor-
tance of performing detailed evaluations of the viable
alternative strategies taken in the context of local prac-
tices, feasible methods of screening organisation, and
clinically acceptable options; rather than generically
applying strategies that may be applicable in other set-
tings. For example, although visual inspection with
cryotherapy see-and-treat has previously been evaluated
as cost-effective in other settings [27], this strategy
would not be acceptable in China. This is because
power supplies for LEEP would be available in the
settings we considered; and the in context of local clini-
cal practice it is felt that the lack of histological diagno-
sis after cryotherapy would potentially increase the risk
of medical disputes and confusion about clinical man-
agement. The local preference for diagnostic confirma-
tion followed by LEEP treatment is emphasised by the
incorporation of this management strategy into a
recently implemented large scale government demon-
stration project for VIA/VILI screening which has the
objective of screening up to 10 million women [37]. Our
evaluation models the VIA/VILI management processes
used in the demonstration project, but also gives local
policy makers much more detailed information on the
relative benefits of careHPV screening. In relation to the
sampling method for HPV testing, we evaluated each
method in context of the associated practically realisable
method(s) of screening organisation, so that self-sam-
pling (which is less costly than health provider sam-
pling) was combined with community/village clinic-
based once- or twice-lifetime screening. Health provider
sampling was combined with county hospital-based reg-
ular screening, which would be viable in this more cen-
tralised approach. However, it should be noted that
because the evidence suggests that both provider and
self-sampling for careHPV testing has relatively high
sensitivity [3], the effectiveness of the two sampling stra-
tegies are also expected to be similar.
The strengths of the current study lie in the detailed
epidemiological modelling and the use of extensive local
information on screening and diagnostic test accuracy
and management practices, age-specific unsatisfactory
rates, and costs. Our study takes into account measured
patterns of sexual behaviour and HPV infection in this
rural population. This has allowed us to characterise in
detail the potential role of primary HPV screening in
relation to other viable alternatives in this important
low-resource setting.
Conclusions
This modelled analysis suggests that primary HPV
screening with careHPV would be an effective and cost-
effective method of primary screening in rural China,
and that it compares favorably to visual inspection
methods in terms of increased effectiveness.
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